Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

PMN

ProMIS Neurosciences Inc.

May 02 • 04:00PM ET

1.99

Dollar change +0.07
Percentage change 3.45	%

Healthcare • Biotechnology • Canada • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.23	Insider Own	24.24%	Shs Outstand	18.89M	Perf Week	1.79%
Market Cap	37.64M	Forward P/E	-	EPS next Y	-0.51	Insider Trans	0.00%	Shs Float	14.36M	Perf Month	-2.91%
Income	-13.21M	PEG	-	EPS next Q	-	Inst Own	12.24%	Short Float	0.16%	Perf Quarter	-4.57%
Sales	0.00M	P/S	-	EPS this Y	35.51%	Inst Trans	-	Short Ratio	1.33	Perf Half Y	13.43%
Book/sh	0.20	P/B	9.99	EPS next Y	26.09%	ROA	-128.63%	Short Interest	0.02M	Perf Year	-66.07%
Cash/sh	0.67	P/C	2.98	EPS next 5Y	-	ROE	-1098.51%	52W Range	0.95 - 8.95	Perf YTD	72.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	11.39%	ROI	-352.02%	52W High	-77.82%	Beta	0.71
Dividend TTM	-	Quick Ratio	1.44	Sales past 5Y	18.85%	Gross Margin	-	52W Low	108.95%	ATR (14)	0.23
Dividend Ex-Date	-	Current Ratio	1.44	EPS Y/Y TTM	49.98%	Oper. Margin	0.00%	RSI (14)	47.55	Volatility	12.86% 13.07%
Employees	7	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	19.28
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	79.12%	Payout	-	Rel Volume	0.26	Prev Close	1.92
Sales Surprise	-	EPS Surprise	81.85%	Sales Q/Q	-	Earnings	Apr 01 AMC	Avg Volume	17.34K	Price	1.99
SMA20	-5.96%	SMA50	-3.02%	SMA200	0.83%	Trades		Volume	4,583	Change	3.45%

Apr-30-24 07:00AM	ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies (GlobeNewswire)
Apr-09-24 07:00AM	ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS (GlobeNewswire)
Apr-04-24 07:00AM	ProMIS Neurosciences to Present in Upcoming Investor Conferences in April (GlobeNewswire)
Apr-01-24 10:53PM	PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023 (InvestorPlace) +7.33%
04:15PM	ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights (GlobeNewswire)
07:00AM	Loading…
Mar-11-24 07:00AM	ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio (GlobeNewswire)
Feb-22-24 07:00AM	ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire) -10.14%
Jan-22-24 07:00AM	ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine (GlobeNewswire) +7.24%
Jan-08-24 07:00AM	ProMIS Neurosciences Issues Letter to Shareholders (GlobeNewswire) +5.45%
Jan-03-24 07:00AM	ProMIS Neurosciences, Inc. Announces Leadership Transition (GlobeNewswire) -7.82%
Dec-20-23 07:00AM	ProMIS Neurosciences Announces Publication on Novel Target for ALS (GlobeNewswire)
Nov-20-23 07:00AM	ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease (GlobeNewswire) +6.67%
Nov-14-23 04:30PM	ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire) -12.22%
Sep-08-23 07:00AM	ProMIS Neurosciences Closes $20.4 Million Private Placement Financing (GlobeNewswire)
Sep-06-23 12:18PM	ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
04:12PM	Loading…
Aug-21-23 04:12PM	ProMIS Neurosciences Announces $20.4 Million Private Placement Financing (GlobeNewswire) -9.14%
Aug-14-23 05:33PM	ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Jul-17-23 07:00AM	ProMIS Showcases Preclinical Data at the Alzheimers Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimers Pipeline (GlobeNewswire) +120.28%
Jul-14-23 07:45AM	ProMIS Announces Completion of Continuance (GlobeNewswire)
Jul-10-23 07:55AM	ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange (GlobeNewswire) -8.11%
Jun-30-23 08:00AM	ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved (GlobeNewswire)
Jun-29-23 08:00AM	CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time (GlobeNewswire)
May-15-23 05:00PM	ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
May-08-23 09:00AM	ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimers Disease (GlobeNewswire)
Apr-25-23 05:00PM	Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimers Disease (GlobeNewswire)
Apr-24-23 07:30AM	ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimers Disease and ALS at American Academy of Neurology Annual Meeting (GlobeNewswire) +8.31%
Apr-10-23 07:30AM	ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310 (GlobeNewswire)
Mar-29-23 08:30AM	Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023 (GlobeNewswire)

ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PMN

ProMIS Neurosciences Inc.

Upgrade your FINVIZ experience